Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 11.45
+0.02 (0.17%)
Apr 29, 2026, 3:04 PM CST
SHE:301211 Revenue
Hubei Biocause Heilen Pharmaceutical had revenue of 120.16M CNY in the quarter ending March 31, 2026, with 5.00% growth. This brings the company's revenue in the last twelve months to 459.02M, up 8.71% year-over-year. In the year 2025, Hubei Biocause Heilen Pharmaceutical had annual revenue of 453.31M with 1.67% growth.
Revenue (ttm)
459.02M
Revenue Growth
+8.71%
P/S Ratio
10.40
Revenue / Employee
482.17K
Employees
952
Market Cap
4.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 453.31M | 7.44M | 1.67% |
| Dec 31, 2024 | 445.86M | -217.16M | -32.75% |
| Dec 31, 2023 | 663.03M | 148.11M | 28.76% |
| Jan 1, 2023 | 514.91M | -25.71M | -4.76% |
| Jan 1, 2022 | 540.62M | -52.30M | -8.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.35B |
| Jinling Pharmaceutical Company | 3.20B |
| Yabao Pharmaceutical Group | 2.20B |
| Hunan Fangsheng Pharmaceutical | 1.79B |
| Fuan Pharmaceutical (Group) | 1.71B |
| Bide Pharmatech | 1.32B |
| Tibet Weixinkang Medicine | 1.16B |
| Nanjing Hicin Pharmaceutical | 688.74M |